Patents by Inventor Malcolm Maccoss

Malcolm Maccoss has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220289685
    Abstract: A series of 2-imino-6-methylhexahydropyrimidin-4-one derivatives, and analogues thereof, substituted in the 6-position by an arylcarbonylaminophenyl or heteroarylcarbonylaminophenyl moiety, being potent inhibitors of the growth and propagation of the Plasmodium falciparum parasite in human blood, are beneficial as pharmaceutical agents, especially in the treatment of malaria.
    Type: Application
    Filed: August 17, 2020
    Publication date: September 15, 2022
    Inventors: Teresa De Haro Garcia, Martin Alexander Lowe, Malcolm MacCoss, Richard David Taylor, Zhaoning Zhu, Rose Elizabeth Chappell
  • Publication number: 20220112184
    Abstract: The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Application
    Filed: September 24, 2021
    Publication date: April 14, 2022
    Inventors: Nobuyuki MATSUNAGA, Yasufumi MIYAMOTO, Junya SHIRAI, Takashi NAKAHATA, Zenyu SHIOKAWA, Tomohiro OKAWA, Akito SHIBUYA, Malcolm MACCOSS
  • Publication number: 20220098207
    Abstract: The present invention provides a fused heteroaryl compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 24, 2021
    Publication date: March 31, 2022
    Inventors: Nobuyuki MATSUNAGA, Junya SHIRAI, Tomohiro OKAWA, Yasufumi MIYAMOTO, Zenyu SHIOKAWA, Takashi NAKAHATA, Akito SHIBUYA, Akira KAWADA, Malcolm MACCOSS
  • Patent number: 11136310
    Abstract: A series of 2-imino-6-methyltetrahydropyrimidin-4(1H)-one derivatives, substituted in the 6-position by a phenyl moiety which in turn is meta-substituted by an optionally substituted unsaturated fused bicyclic ring system containing at least one nitrogen atom, being selective inhibitors of plasmepsin V activity, are beneficial as pharmaceutical agents, especially in the treatment of malaria.
    Type: Grant
    Filed: November 24, 2016
    Date of Patent: October 5, 2021
    Assignee: UCB Biopharma SRL
    Inventors: Rebecca Louise Charlton, Teresa De Haro Garcia, Martin Alexander Lowe, Malcolm Maccoss, Trevor Morgan, Richard David Taylor, Zhaoning Zhu
  • Patent number: 11130752
    Abstract: The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: September 24, 2019
    Date of Patent: September 28, 2021
    Assignee: Cardurion Pharmaceuticals, LLC
    Inventors: Nobuyuki Matsunaga, Yasufumi Miyamoto, Junya Shirai, Takashi Nakahata, Zenyu Shiokawa, Tomohiro Okawa, Akito Shibuya, Malcolm MacCoss
  • Publication number: 20210252012
    Abstract: A compound of formula (I) as defined herein, or a pharmaceutically acceptable salt thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Application
    Filed: February 15, 2021
    Publication date: August 19, 2021
    Inventors: Daniel Christopher Brookings, Teresa De Haro Garcia, Yann Foricher, Helen Tracey Horsley, Martin Clive Hutchings, James Andrew Johnson, Malcolm Maccoss, Mengyang Xuan, Zhaoning Zhu
  • Patent number: 11091474
    Abstract: The present invention relates to certain bis-heteroaryl compounds, pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and methods of treating diseases that are associated with protein aggregation, including neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Lewy body disease, Parkinson's disease with dementia, fronto-temporal dementia, Huntington's Disease, amyotrophic lateral sclerosis, and multiple system atrophy, and cancer including melanoma.
    Type: Grant
    Filed: January 23, 2018
    Date of Patent: August 17, 2021
    Assignee: UCB Biopharma SRL
    Inventors: Adrian Hall, Malcolm Maccoss
  • Patent number: 10980814
    Abstract: Disclosed herein are compounds of formula (I) and pharmaceutically acceptable salt thereof, wherein variables X, R1, R2, and R3 are defined herein. These compounds are potent modulators of human TNF? activity and, accordingly, of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: April 20, 2021
    Assignees: UCB Biopharma SRL, Sanofi
    Inventors: Daniel Christopher Brookings, Teresa De Haro Garcia, Yann Foricher, Helen Tracey Horsley, Martin Clive Hutchings, James Andrew Johnson, Malcolm Maccoss, Mengyang Xuan, Zhaoning Zhu
  • Patent number: 10975066
    Abstract: The present invention relates to certain bis-heteroaryl compounds, pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and methods of treating diseases that are associated with protein aggregation, including neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Lewy body disease, Parkinson's disease with dementia, fronto-temporal dementia, Huntington's Disease, amyotrophic lateral sclerosis, and multiple system atrophy, and cancer including melanoma.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: April 13, 2021
    Assignee: UCB Biopharma SRL
    Inventors: Wolfgang Wrasidlo, Emily M. Stocking, Adrian Hall, Malcolm Maccoss
  • Publication number: 20210094941
    Abstract: The application relates to a series of 2-imino-6-methylhexahydropyrimidin-4-one derivatives and 3-imino-5-methyl-1,2,4-thiadiazinane 1,1-dioxide derivatives of formula (I), substituted by an arylaminophenyl or heteroarylaminophenyl moiety. The compounds are potent inhibitors of the growth and propagation of the Plasmodium falciparum parasite in human blood and thus useful as pharmaceutical agents for the treatment of malaria.
    Type: Application
    Filed: April 2, 2019
    Publication date: April 1, 2021
    Inventors: Teresa De Haro Garcia, Lloyd Malcolm King, Martin Alexander Lowe, Malcolm Maccoss, Richard David Taylor, Zhaoning Zhu
  • Patent number: 10889584
    Abstract: The present invention relates to certain bicyclic bis-heteroaryl compounds of Formula (I), pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and methods of treating diseases that are associated with protein aggregation, including neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Lewy body disease, Parkinson's disease with dementia, fronto-temporal dementia, Huntington's Disease, amyotrophic lateral sclerosis, and multiple system atrophy, and cancer including melanoma.
    Type: Grant
    Filed: January 23, 2018
    Date of Patent: January 12, 2021
    Assignee: UCB Biopharma SRL
    Inventors: Adrian Hall, Laurent Provins, Malcolm Maccoss
  • Publication number: 20200291013
    Abstract: The present invention relates to certain bis-heteroaryl compounds, pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and methods of treating diseases that are associated with protein aggregation, including neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Lewy body disease, Parkinson's disease with dementia, fronto-temporal dementia, Huntington's Disease, amyotrophic lateral sclerosis, and multiple system atrophy, and cancer including melanoma.
    Type: Application
    Filed: January 23, 2018
    Publication date: September 17, 2020
    Applicant: UCB Biopharma SPRL
    Inventors: Adrian HALL, Malcolm MACCOSS
  • Publication number: 20200283416
    Abstract: A series of 2-imino-6-methyltetrahydropyrimidin-4(1H)-one derivatives, substituted in the 6-position by a phenyl moiety which in turn is meta-substituted by an optionally substituted unsaturated fused bicyclic ring system containing at least one nitrogen atom, being selective inhibitors of plasmepsin V activity, are beneficial as pharmaceutical agents, especially in the treatment of malaria.
    Type: Application
    Filed: November 24, 2016
    Publication date: September 10, 2020
    Inventors: Rebecca Louise Charlton, Teresa De Haro Garcia, Martin Alexander Lowe, Malcolm Maccoss, Trevor Morgan, Richard David Taylor, Zhaoning Zhu
  • Publication number: 20200206221
    Abstract: The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
    Type: Application
    Filed: March 6, 2020
    Publication date: July 2, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Scott D. Edmondson, Michael H. Fischer, Dooseop Kim, Malcolm Maccoss, Emma R. Parmee, Ann E. Weber, Jinyou Xu
  • Publication number: 20200095240
    Abstract: The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Application
    Filed: September 24, 2019
    Publication date: March 26, 2020
    Inventors: Nobuyuki MATSUNAGA, Yasufumi MIYAMOTO, Junya SHIRAI, Takashi NAKAHATA, Zenyu SHIOKAWA, Tomohiro OKAWA, Akito SHIBUYA, Malcolm MacCoss
  • Publication number: 20200046723
    Abstract: A compound of formula (I) as defined herein, or a pharmaceutically acceptable salt thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Application
    Filed: April 24, 2018
    Publication date: February 13, 2020
    Inventors: Daniel Christopher Brookings, Teresa De Haro Garcia, Yann Foricher, Helen Tracey Horsley, Martin Clive Hutchings, James Andrew Johnson, Malcolm Maccoss, Mengyang Xuan, Zhaoning Zhu
  • Publication number: 20190367513
    Abstract: The present invention relates to certain bicyclic bis-heteroaryl compounds of Formula (I), pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and methods of treating diseases that are associated with protein aggregation, including neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Lewy body disease, Parkinson's disease with dementia, fronto-temporal dementia, Huntington's Disease, amyotrophic lateral sclerosis, and multiple system atrophy, and cancer including melanoma.
    Type: Application
    Filed: January 23, 2018
    Publication date: December 5, 2019
    Applicant: UCB Biopharma SPRL
    Inventors: Adrian HALL, Laurent PROVINS, Malcolm MACCOSS
  • Patent number: 10464932
    Abstract: A series of 3-imino-5-methyl-1,2,4-thiadiazinane 1,1-dioxide derivatives of formula (I), substituted in the 5-position by a phenyl moiety NH which in turn is meta-substituted by an optionally substituted fused bicyclic heteroaromatic ring system containing at least one nitrogen atom, being selective inhibitors of plasmepsin V activity, are beneficial as pharmaceutical agents, especially in the treatment of malaria.
    Type: Grant
    Filed: February 22, 2017
    Date of Patent: November 5, 2019
    Assignee: UCB Biopharma SPRL
    Inventors: Teresa De Haro Garcia, Martin Alexander Lowe, Malcolm Maccoss, Richard David Taylor, Zhaoning Zhu
  • Publication number: 20190040053
    Abstract: A series of 3-imino-5-methyl-1,2,4-thiadiazinane 1,1-dioxide derivatives of formula (I), substituted in the 5-position by a phenyl moiety NH which in turn is meta-substituted by an optionally substituted fused bicyclic heteroaromatic ring system containing at least one nitrogen atom, being selective inhibitors of plasmepsin V activity, are beneficial as pharmaceutical agents, especially in the treatment of malaria.
    Type: Application
    Filed: February 22, 2017
    Publication date: February 7, 2019
    Inventors: Teresa De Haro Garcia, Martin Alexander Lowe, Malcolm Maccoss, Richard David Taylor, Zhaoning Zhu
  • Patent number: 10087179
    Abstract: A series of fused tricyclic imidazole derivatives, in particular dihydro-1H-cyclopenta[4,5]imidazo[1,2-a]pyridine derivatives, and analogues thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: October 2, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Rikki Peter Alexander, Gareth Neil Brace, Julien Alistair Brown, Mark Daniel Calmiano, Prafulkumar Tulshibhai Chovatia, Michael Deligny, Ellen Olivia Gallimore, Jag Paul Heer, Victoria Elizabeth Jackson, Boris Kroeplien, Malcolm MacCoss, Joanna Rachel Quincey, Yogesh Anil Sabnis, Dominique Louis Léon Swinnen, Zhaoning Zhu, Uwe Heinelt, Volkmar Wehner